BCDA - BioCardia, Inc.
IEX Last Trade
2.26
0.085 3.761%
Share volume: 1,039
Last Updated: Thu 26 Dec 2024 08:20:09 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
-0.11%
PREVIOUS CLOSE
CHG
CHG%
$2.18
0.09
3.91%
Fundamental analysis
31%
Profitability
43%
Dept financing
16%
Liquidity
61%
Performance
15%
Performance
5 Days
-0.50%
1 Month
-12.28%
3 Months
-27.54%
6 Months
-31.03%
1 Year
-79.49%
2 Year
-92.63%
Key data
Stock price
$2.26
DAY RANGE
$1.91 - $2.18
52 WEEK RANGE
$2.01 - $10.79
52 WEEK CHANGE
-$79.63
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/06/2024
Company detail
CEO: Peter Alan Altman, PhD
Region: US
Website: biocardia.com
Employees: 40
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: biocardia.com
Employees: 40
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
BioCardia, Inc. develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Its lead therapeutic candidate is the CardiAMP Cell Therapy System for the treatment of heart failure and chronic myocardial ischemia. The company is also developing allogeneic cells therapeutic platform, an investigational culture expanded bone marrow derived mesenchymal cell therapy.
Recent news